
Conference Coverage
about 2 hours ago
SONO 2026: Kelsey Martin on a Busy Year for Breast Cancer ApprovalsLatest Content

Oral SERDs: What Giredestrant Signals for Nurses

SONO 2026: Kelsey Martin on a Busy Year for Breast Cancer Approvals

AI Can Help Find Patients for Lung Screening, but Nurses Stay in the Loop

Chris Draft: Make Survivorship the Goal to Counter Lung Cancer Stigma

SONO 2026: Donna Catamero on Defining Cure as Myeloma Outcomes Improve

Shorts










Videos
Continuing Medical Education
All News

An ONS nursing practice leader shares takeaways from EONS19 at ESMO 2026, from workforce sustainability to new therapies and subcutaneous care.

Erica L. Mayer, MD, MPH, explains what the all-oral giredestrant plus everolimus regimen asks of patients and oncology nurses between clinic visits.

Jan Franko, MD, PhD, explains how integrated teams of nurses, nurse practitioners, and navigators help patients get complex cancer care near home.

Former NFL linebacker Chris Draft shares how his late wife's lung cancer launched Team Draft and how nurses help families decode a new diagnosis.

The supplement, sold in Europe as OnLife, was evaluated in the single-arm STEFANO study of 146 patients with paclitaxel- or oxaliplatin-induced CIPN.

The evERA principal investigator explains ESR1 testing, bradycardia and stomatitis prevention, and oral adherence with giredestrant plus everolimus.

Beth Sandy, MSN, CRNP, FAPO, reviewed ADCs, immunotherapy, and targeted therapy in NSCLC with a focus on what nurses should monitor.

Neladalkib produced response rates of 49% after alectinib and 32% after multiple ALK TKIs plus chemotherapy in the ALKOVE-1 trial.

JoAnne Page, RN, a breast cancer survivor, shares what oncology nurses can do for care partners of patients with bladder cancer.

Giredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.

Alembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.

The field of oncology continues to evolve, driven by novel drug approvals, innovative delivery technologies, and emerging care strategies in cancer survivorship.

Pertuzumab-qcay is the second FDA-approved biosimilar to Perjeta, but a settlement with Genentech delays its US launch until Q3 2028.

The FDA declined to approve ivonescimab plus chemotherapy after EGFR TKI therapy, citing no statistically significant OS gain in HARMONi.

Cancer care teams are supporting more patients than ever, and oncology teams are navigating the clinical and operational realities that come with that growth.

























































